Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

HIGH THROUGHPUT ELISA CHIP FOR DRUG TOXICITY SCREENING

Award Number: R44GM075529
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/28/2005
PERIOD OF PERFORMANCE END DATE: 08/31/2009

Group Awards By:

View Award Description

HIGH THROUGHPUT ELISA CHIP FOR DRUG TOXICITY SCREENING - DESCRIPTION (provided by applicant): High throughput ELISA chip for drug toxicity screening Summary Adverse drug metabolism, drug-drug interactions, and direct toxicity effects have caused numerous drug failures. High throughput biomarker profiling offers the potential to predict drug toxicity to help reduce pipeline attrition. Reaction Biology Corporation has developed extremely low cost nanoliter reaction microarrays to serve markets for ultra high throughput screening (uHTS), large scale IC50 determinations, and selectivity profiling in drug discovery. These reactions are 1000 to 10,000-fold smaller than well plate formats currently used widely in drug discovery. Based on Phase I data demonstrating high sensitivity profiling of cellular antigens, we propose to create microarray products and technologies capable of evaluating drug-induced hepatotoxicity by screening large numbers of cell lysates obtained from cells treated with chemical compounds or their combinations. The following specific aims for Phase II research include: Aim 1 Develop and validate detection protocols for over 30 toxic-biomarkers involved in drug-induced liver toxicity testing. These markers will serve as the basis for the HepTox-chip(r) (hepatocyte toxic biomarkers antibody microarray) and for the Mi-HTS(r) (microarray immunoassay for high throughput screening) service offering. Aim 2 Establish a compound library including common over-the-counter and prescription drugs and test their hepatotoxicity profiles with HepTox-chip(r) and Mi-HTS(r) chip. This aim will be particularly useful for identifying unexpected drug- drug interactions of new chemical entities. Aim 3 Develop the Toxic-Informatics Database (ToxID(r)) by integrating the publicly available information related to biomarkers from Aim 1 in genomic, proteomic and clinic tests with common drugs tested in Aim 2 as a predictive tool for hepatotoxicity. The central goal of the proposed Phase II efforts is to develop two antibody microarray based products, one a marketable and user-friendly microarray chip detecting over 30 protein toxic-biomarkers and the other a service package that RBC provides for analyzing a large number of chemicals effects (e.g. test compound crossed against the OTC/prescription drug library) on hepatocyte toxic biomarker expression. Drug-induced liver toxicity is the major cause of drug-induced death and the principle reason for withdrawal of drugs from the market (Waring, 2003) and Food and Drug Adminstration (FDA) already sees toxicogenomic's potential in proving hypotheses that support safe drug use in humans through a mechanistic understanding of toxicities found in drug-treated animals (Lord & Papoian, 2004). The toxicoproteomic is a relatively new area that could have similar function but with more directed and precisely detection, because monitoring protein expression changes is more relevant than monitoring gene changes (Wetmore & Merrick, 2004; Kikkawa et al, 2006; Yamamoto et al, 2005).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2008 ( Subtotal = $442,588 )
2008	2008	REACTION BIOLOGY CORPORATION	1764 LITCHFIELD TURNPIKE, 203	WOODBRIDGE	CT	06525	SOUTH CENTRAL CT	USA	Biomedical Research and Research Training	000	3	9/16/2008	NON-COMPETING CONTINUATION	$442,588
														Subtotal = $442,588

Issue Date FY: 2007 ( Subtotal = $463,506 )
2007	2007	REACTION BIOLOGY CORPORATION	1764 LITCHFIELD TURNPIKE, 203	WOODBRIDGE	CT	06525	SOUTH CENTRAL CT	USA	Biomedical Research and Research Training	000	2	9/28/2007	COMPETING CONTINUATION	$463,506
														Subtotal = $463,506

Grand Total All Awards = $906,094

Top

All Categories

About

Search

Reports

Data Submission

Award Information

HIGH THROUGHPUT ELISA CHIP FOR DRUG TOXICITY SCREENING

Award Number: R44GM075529

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/28/2005

PERIOD OF PERFORMANCE END DATE: 08/31/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer